LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CRISPR Genome-Editing System Avoids DNA Strand Breaks

By LabMedica International staff writers
Posted on 29 Aug 2018
Image: A model of the cytidine deaminase enzyme, which is a component of the single-base gene-editing system (Photo courtesy of Wikimedia Commons).
Image: A model of the cytidine deaminase enzyme, which is a component of the single-base gene-editing system (Photo courtesy of Wikimedia Commons).
A variation of the CRISPR/Cas9 genome-editing tool enables more precise manipulation of target genes by not breaking double stranded DNA and instead modifying a single point in the targeted DNA sequence.

CRISPR gene editing has revolutionized biomedicine and biotechnology by providing a simple means to engineer genes through targeted double-strand breaks in the genomic DNA of living cells. However, given the random nature of cellular DNA repair mechanisms and the potential for off-target mutations, technologies capable of introducing targeted changes with increased precision, such as single-base editors, are preferred.

In this regard, a single-base editing system called CRISPR-SKIP was described by investigators at the University of Illinois (Champaign, USA) in the August 15, 2018, online edition of the journal Genome Biology. This method utilized cytidine deaminase single-base editors to program exon skipping by mutating target DNA bases within splice acceptor sites. Thus, CRISPR-SKIP altered a single base before the beginning of an exon, causing the cell to read it as a non-coding portion.

The modified exon was not included in mature RNA, which prevented the corresponding amino acids from becoming part of the protein product. Proteins that are missing a few amino acids often retain partial or full activity, which may be enough to restore function in some genetic diseases.

"Given the problems with traditional gene editing by breaking the DNA, we have to find ways of optimizing tools to accomplish gene modification. This is a good one because we can regulate a gene without breaking genomic DNA," said senior author Dr. Pablo Perez-Pinera, professor of bioengineering at the University of Illinois.

"In Duchenne's muscular dystrophy, for example, just correcting 5% to 10% of the cells is enough to achieve a therapeutic benefit. With CRISPR-SKIP, we have seen modification rates of more than 20% to 30% in many of the cell lines we have studied," said Dr. Perez-Pinera.

Related Links:
University of Illinois

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Homocysteine Quality Control
Liquichek Homocysteine Control

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more